Bridge Biotherapeutics has joined the Prognostic Lung Fibrosis Consortium, known as PROLIFIC — a global nonprofit working to speed the development of personalized treatment strategies for pulmonary fibrosis (PF), The long-term goal of PROLIFIC is to develop tests to detect biomarkers of distinct stages of the rare…
News
Treatment with a molecule designed to activate the SHP-1 protein led to prolonged survival and alleviation of disease-associated lung changes in a mouse model of idiopathic pulmonary fibrosis (IPF), a study found. SHP-1 activation appeared to exert its protective effects by inhibiting the survival and pro-fibrotic activity of a…
Ofev (nintedanib) more than halved the rate of lung function decline in patients who developed interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), an inflammatory disease. That’s according to data from INBUILD (NCT02999178), a Phase 3 trial of more than 650 adults with progressive fibrosing ILDs in…
A Phase 3 trial of pamrevlumab, an experimental therapy from FibroGen to treat idiopathic pulmonary fibrosis (IPF), failed to meet its primary goal of slowing lung function decline. General safety and tolerability were seen in treated patients in ZEPHYRUS-1 (NCT03955146), which tested 48 weeks of pamrevlumab’s use…
Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed using artificial intelligence (AI), as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patients have now received the first dose of oral INS018_055 in a randomized placebo-controlled Phase 2…
A new, potentially disease-specific imaging agent may one day allow doctors to identify pulmonary fibrosis (PF) in earlier stages, when the start of treatment can be more effective, according to a study in a mouse model of the disease. Called 64Cu-GPVI-Fc, the agent — coupled with positron emission tomography…
Researchers in the U.S. turned a special type of mouse stem cell into green, glowing lung cells in the lab and now have a limitless supply they can use as a model to study how pulmonary fibrosis and other lung diseases develop. “Our study has implications for the study…
The U.S. Food and Drug Administration has given the green light for Mabwell Therapeutics to launch a clinical trial testing 9MW3811, its injectable treatment candidate for idiopathic pulmonary fibrosis (IPF) and cancer, according to a company press release. Last month, the National Medical Products Administration in…
The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed to meet its primary or secondary goals, according to recent top-line data. “The REBUILD study did not match the outcomes we…
When used in a real-world setting, Ofev (nintedanib) significantly prolonged the survival of idiopathic pulmonary fibrosis (IPF) patients, according to an analysis of Czech registry data. Yet, Ofev was not associated with a significant slowing of lung function decline or with other estimations of disease progression. Findings were…
